zw191
·Code: ZW191
zw191: developed by 1 company · 1 clinical trial tracked.
zw191 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect zw191 to ZYME; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could zw191 → ZYME affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Zymeworks Inc. (ZYME) | Phase 1 |
Clinical Trials (1)
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
Primary endpoint: Incidence of dose-limiting toxicities (DLTs; Part 1)
Interventionalopen145 targetStarted 2024-10Completion 2027-0127 sites · Australia, Japan, Singapore, South Korea…Zymeworks BC Inc.
Frequently asked questions
Who is developing zw191?
zw191 is being developed by Zymeworks Inc..
How many clinical trials involve zw191?
BioSniper tracks 1 clinical trial involving zw191.